1. Home
  2. GERN vs IVA Comparison

GERN vs IVA Comparison

Compare GERN & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.47

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$5.42

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GERN
IVA
Founded
1990
2011
Country
United States
France
Employees
229
77
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GERN
IVA
Price
$1.47
$5.42
Analyst Decision
Hold
Strong Buy
Analyst Count
3
10
Target Price
$2.17
$16.20
AVG Volume (30 Days)
14.8M
355.4K
Earning Date
05-06-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$26.91
N/A
Revenue Next Year
$43.75
$751.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.04
$2.94
52 Week High
$2.01
$7.98

Technical Indicators

Market Signals
Indicator
GERN
IVA
Relative Strength Index (RSI) 41.74 50.93
Support Level $1.44 $4.90
Resistance Level $1.49 $6.42
Average True Range (ATR) 0.09 0.21
MACD -0.00 0.05
Stochastic Oscillator 16.13 61.28

Price Performance

Historical Comparison
GERN
IVA

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: